{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:17:10Z","timestamp":1772781430263,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.pupt.2008.08.001","type":"journal-article","created":{"date-parts":[[2008,8,18]],"date-time":"2008-08-18T08:02:08Z","timestamp":1219046528000},"page":"845-854","source":"Crossref","is-referenced-by-count":43,"title":["Advantageous toxicity profile of inhaled antisense oligonucleotides following chronic dosing in non-human primates"],"prefix":"10.1016","volume":"21","author":[{"given":"Alain","family":"Guimond","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Viau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pam\u00e9la","family":"Aub\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo M.","family":"Renzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolay","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.taap.2004.04.017","article-title":"Toxicology of antisense therapeutics","volume":"201","author":"Jason","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"issue":"8","key":"10.1016\/j.pupt.2008.08.001_bib3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","article-title":"Antisense technologies: improvement through novel chemical modifications","volume":"270","author":"Kurreck","year":"2003","journal-title":"Eur J Biochem"},{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0167-4781(99)00140-2","article-title":"A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides","volume":"1489","author":"Levin","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1196\/annals.1348.032","article-title":"Characterization of antisense oligonucleotides comprising 2\u2032-deoxy-2\u2032-fluoro-beta-d-arabinonucleic acid (FANA): specificity, potency, and duration of activity","volume":"1082","author":"Ferrari","year":"2006","journal-title":"Ann NY Acad Sci"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib6","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1074\/jbc.274.3.1715","article-title":"Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression","volume":"274","author":"McKay","year":"1999","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/108729002760220734","article-title":"GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation","volume":"12","author":"Sternberger","year":"2002","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"10","key":"10.1016\/j.pupt.2008.08.001_bib8","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1073\/pnas.97.10.5633","article-title":"Potent and nontoxic antisense oligonucleotides containing locked nucleic acids","volume":"97","author":"Wahlestedt","year":"2000","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.pupt.2008.08.001_bib9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/nar\/gkh516","article-title":"2\u2032-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro","volume":"32","author":"Yoo","year":"2004","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1196\/annals.1348.047","article-title":"Multitargeted approach using antisense oligonucleotides for the treatment of asthma","volume":"1082","author":"Allakhverdi","year":"2006","journal-title":"Ann NY Acad Sci"},{"issue":"7","key":"10.1016\/j.pupt.2008.08.001_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1164\/ajrccm.165.7.2109095","article-title":"Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma","volume":"165","author":"Allakhverdi","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.pupt.2008.08.001_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1089\/108729001753231678","article-title":"Inhibition of GM-CSF\/IL-3\/IL-5 signaling by antisense oligodeoxynucleotides targeting the common beta chain of their receptors","volume":"11","author":"Allam","year":"2001","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/oli.2006.16.203","article-title":"Effects of antisense oligodeoxynucleotides targeting CCR3 on the airway response to antigen in rats","volume":"16","author":"Fortin","year":"2006","journal-title":"Oligonucleotides"},{"issue":"28","key":"10.1016\/j.pupt.2008.08.001_bib14","doi-asserted-by":"crossref","first-page":"16491","DOI":"10.1074\/jbc.270.28.16491","article-title":"Cloning and functional expression of a human eosinophil CC chemokine receptor","volume":"270","author":"Combadiere","year":"1995","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib15","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1006\/bbrc.1993.2599","article-title":"The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo","volume":"197","author":"Griffiths-Johnson","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib16","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1084\/jem.179.3.881","article-title":"Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation","volume":"179","author":"Jose","year":"1994","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.pupt.2008.08.001_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0196-0709(97)90003-X","article-title":"Interleukin-3 interleukin-5, and granulocyte-macrophage colony-stimulating factor expression in nasal polyps","volume":"18","author":"Allen","year":"1997","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"10.1016\/j.pupt.2008.08.001_bib18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/02770909709075659","article-title":"Stimulation of blood mononuclear cells of atopic children with the relevant allergen induces the release of eosinophil chemotaxins such as IL-3, IL-5, and GM-CSF","volume":"34","author":"Lantero","year":"1997","journal-title":"J Asthma"},{"issue":"21","key":"10.1016\/j.pupt.2008.08.001_bib19","doi-asserted-by":"crossref","first-page":"9565","DOI":"10.1073\/pnas.92.21.9565","article-title":"Hematopoietic and lung abnormalities in mice with a null mutation of the common {beta} subunit of the receptors for granulocyte-macrophage colony-stimulating factor and Interleukins 3 and 5","volume":"92","author":"Robb","year":"1995","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.pupt.2008.08.001_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jaci.2003.08.015","article-title":"Biology of common [beta] receptor-signaling cytokines: IL-3, IL-5, and GM-CSF","volume":"112","author":"Shearer","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"1\u20133","key":"10.1016\/j.pupt.2008.08.001_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejphar.2005.12.056","article-title":"Adenosine in the airways: implications and applications","volume":"533","author":"Spicuzza","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pupt.2008.08.001_bib22","doi-asserted-by":"crossref","unstructured":"Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced responses. Am J Respir Crit Care Med 2008; 200708-201251OC.","DOI":"10.1164\/rccm.200708-1251OC"},{"issue":"12","key":"10.1016\/j.pupt.2008.08.001_bib23","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.4049\/jimmunol.173.12.7531","article-title":"Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation","volume":"173","author":"Ariga","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib24","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.4049\/jimmunol.175.3.1523","article-title":"Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages","volume":"175","author":"Jin","year":"2005","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0898-6568(01)00250-9","article-title":"PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP","volume":"14","author":"Lee","year":"2002","journal-title":"Cell Signal"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1365-2249.2002.01856.x","article-title":"Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors","volume":"128","author":"Nakata","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pupt.2008.08.001_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1054-3589(08)60125-8","article-title":"The role of phosphodiesterase enzymes in allergy and asthma","volume":"44","author":"Spina","year":"1998","journal-title":"Adv Pharmacol"},{"issue":"5","key":"10.1016\/j.pupt.2008.08.001_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bbadis.2005.12.009","article-title":"The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats","volume":"1762","author":"Tang","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"1\u20133","key":"10.1016\/j.pupt.2008.08.001_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2005.12.059","article-title":"Phosphodiesterase inhibitors in airways disease","volume":"533","author":"Fan Chung","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"25","key":"10.1016\/j.pupt.2008.08.001_bib30","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.2174\/138161206778194123","article-title":"Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation?","volume":"12","author":"Giembycz","year":"2006","journal-title":"Curr Pharm Des"},{"issue":"27","key":"10.1016\/j.pupt.2008.08.001_bib31","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.2174\/092986706778773040","article-title":"Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD","volume":"13","author":"Huang","year":"2006","journal-title":"Curr Med Chem"},{"issue":"10","key":"10.1016\/j.pupt.2008.08.001_bib32","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1023\/A:1015048419558","article-title":"Distribution of a 20-Mer phosphorothioate oligonucleotide, CGP69846A (ISIS 5132), into airway leukocytes and epithelial cells following intratracheal delivery to Brown\u2013Norway rats","volume":"16","author":"Danahay","year":"1999","journal-title":"Pharm Res"},{"issue":"11","key":"10.1016\/j.pupt.2008.08.001_bib33","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1124\/dmd.31.11.1419","article-title":"Pharmacokinetics of a tumor necrosis factor-{alpha} phosphorothioate 2\u2032-o-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species","volume":"31","author":"Geary","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.pupt.2008.08.001_bib34","first-page":"1272","article-title":"Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression","volume":"25","author":"Geary","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.pupt.2008.08.001_bib35","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0022-3565(24)38831-7","article-title":"Pharmacokinetic properties of 2\u2032-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats","volume":"296","author":"Geary","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pupt.2008.08.001_bib36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/oli.1.2000.10.359","article-title":"Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice","volume":"10","author":"Templin","year":"2000","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"2","key":"10.1016\/j.pupt.2008.08.001_bib37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/1520-6017(200102)90:2<182::AID-JPS9>3.0.CO;2-F","article-title":"Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey","volume":"90","author":"Yu","year":"2001","journal-title":"J Pharm Sci"},{"issue":"17","key":"10.1016\/j.pupt.2008.08.001_bib38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/jnci\/dji252","article-title":"A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2\u2032-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer","volume":"97","author":"Chi","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.pupt.2008.08.001_bib39","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1158\/1078-0432.CCR-04-2145","article-title":"A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer","volume":"11","author":"Tolcher","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.pupt.2008.08.001_bib40","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1164\/ajrccm.163.4.9907078","article-title":"Absorption, distribution, metabolism, and excretion of a respirable Antisense Oligonucleotide for asthma","volume":"163","author":"Ali","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.pupt.2008.08.001_bib41","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/1099-1263(200007\/08)20:4<273::AID-JAT657>3.0.CO;2-X","article-title":"Allometric respiration\/body mass data for animals to be used for estimates of inhalation toxicity to young adult humans","volume":"20","author":"Bide","year":"2000","journal-title":"J Appl Toxicol"},{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/abio.2002.5576","article-title":"Development of an ultrasensitive noncompetitive hybridization\u2013ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma","volume":"304","author":"Yu","year":"2002","journal-title":"Anal Biochem"},{"issue":"2","key":"10.1016\/j.pupt.2008.08.001_bib43","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/oli.2005.15.119","article-title":"Quantification of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis","volume":"15","author":"Efler","year":"2005","journal-title":"Oligonucleotides"},{"issue":"5","key":"10.1016\/j.pupt.2008.08.001_bib44","first-page":"383","article-title":"Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides","volume":"12","author":"Geary","year":"1997","journal-title":"Anticancer Drug Des"},{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/jps.10473","article-title":"Tissue disposition of 2\u2032-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys","volume":"93","author":"Yu","year":"2004","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.pupt.2008.08.001_bib46","first-page":"1272","article-title":"Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression","volume":"25","author":"Geary","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.pupt.2008.08.001_bib47","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S1567-5769(02)00142-X","article-title":"Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide","volume":"2","author":"Henry","year":"2002","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"10.1016\/j.pupt.2008.08.001_bib48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1089\/oli.1.1997.7.503","article-title":"Inhibition of coagulation by a phosphorothioate oligonucleotide","volume":"7","author":"Henry","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.pupt.2008.08.001_bib49","series-title":"Handbook of experimental pharmacology","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-642-58785-6_5","article-title":"Toxicity of oligonucleotide therapeutic agents","author":"Levin","year":"1998"},{"issue":"4","key":"10.1016\/j.pupt.2008.08.001_bib50","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3181\/00379727-211-43979","article-title":"Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats","volume":"211","author":"Reasor","year":"1996","journal-title":"Proc Soc Exp Biol Med"},{"issue":"4","key":"10.1016\/j.pupt.2008.08.001_bib51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","article-title":"Drug-induced phospholipidosis: issues and future directions","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.pupt.2008.08.001_bib52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.1984.69","article-title":"Early effects of gentamicin, tobramycin, and amikacin on the human kidney","volume":"25","author":"De Broe","year":"1984","journal-title":"Kidney Int"},{"key":"10.1016\/j.pupt.2008.08.001_bib53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00148581-200709001-00003","article-title":"Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"9","author":"Lenoir","year":"2007","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.pupt.2008.08.001_bib54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/exmp.1995.1002","article-title":"In vivo and in vitro reversibility of chlorphentermine-induced phospholipidosis in rat alveolar macrophages","volume":"62","author":"McCloud","year":"1995","journal-title":"Exp Mol Pathol"}],"container-title":["Pulmonary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553908000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553908000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T15:12:19Z","timestamp":1738336339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553908000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1094553908000746"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2008.08.001","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}